Anti-CD (eg, daratumumab) as part of a combination regimen or as a monotherapy Subjects who were not candidates to receive one or more of the above treatments (ie, contraindicated) are eligible.
For Daratumumab + bortezomib + lenalidomide + dexamethasone (D-VRd) and Daratumumab + bortezomib + melphalan + prednisone + dexamethasone (D-VMP) regimen: newly diagnosed myeloma
Any prior therapy with daratumumab
Received daratumumab or other anti-CD therapies previously
Subject has received daratumumab or other anti-CD therapies previously
SY- and daratumumab combination only - Prior or concurrent exposure to daratumumab or other CD therapies.
SY- and daratumumab combination only - Subject has either of the following:
Prior treatment with anti-CD therapy including daratumumab (Cohorts D, D, E, F)
Have received prior ixazomib at any time or daratumumab or other anti-CD therapies, except as part of initial therapy if this was stopped to move on to SCT and the participants did not progress on anti-CD treatment.
Prior daratumumab or other anti-CD antibody
Cancer chemotherapy within  weeks prior to start of daratumumab treatment (steroid or hydroxyurea can be used up to  hours prior to first daratumumab infusion for control of high white cell counts)
Has received prior treatment with daratumumab or other anti-CD therapies previously
Previously received daratumumab or other anti-CD therapies
Participant has received daratumumab or other anti-cluster of differentiation  (anti-CD) therapies previously
Has received daratumumab or other anti-CD therapies previously
Anti-cluster of differentiation(CD) therapy, including daratumumab
Has received any of the following therapies: daratumumab or other anti-CD therapies
Disease progression on daratumumab
Previous therapy with daratumumab or other anti-CD monoclonal antibodies.
Daratumumab or other anti-CD therapies
Patients must have received >=  daratumumab infusions and be scheduled to receive another dose
Prior exposure to daratumumab or prior exposure to other anti-Cluster of Differentiation  (anti-CD) therapies
Daratumumab or other anti CD antibody treatment within  months prior to study enrollment